Indian drug firm Dr Reddy’s Laboratories has started dosing in a randomised, double-blind, placebo-controlled and parallel-group Phase II trial of DRL-17822 in patients suffering from type II dyslipidemia.
DRL-17822, a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein, for the treatment and prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
Go deeper with GlobalData
The study aims to evaluate the safety and efficacy of DRL-17822 in patients with type-II dyslipidemia.
In the study, three doses (50mg, 150mg and 300mg) of DRL-17822 given once daily for four weeks will be investigated.
Three Phase I human studies with DRL-17822 have already been conducted in Europe, and showed the drug to be safe and well tolerated.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
